Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Edwards Lifesciences (NYSE:EW) had its price target upped by equities researchers at JPMorgan Chase & Co. from $105.00 to $120.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 19.16% from the company’s current price.

Several other analysts also recently issued reports on EW. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Thursday. Argus lifted their price target on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 21st. Jefferies Financial Group upped their price target on Edwards Lifesciences from $102.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Truist Financial set a $113.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday. Finally, Citigroup raised their price objective on Edwards Lifesciences from $110.00 to $117.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $107.76.

Edwards Lifesciences Trading Up 1.3%

Shares of Edwards Lifesciences stock traded up $1.33 during trading on Thursday, hitting $100.70. The stock had a trading volume of 9,233,527 shares, compared to its average volume of 4,532,402. The stock has a 50 day simple moving average of $88.48 and a 200 day simple moving average of $85.61. The company has a market capitalization of $57.99 billion, a PE ratio of 57.88, a P/E/G ratio of 2.49 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1 year low of $74.66 and a 1 year high of $104.17.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences will post 3.00 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock valued at $451,596 in the last three months. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in EW. Illinois Municipal Retirement Fund increased its holdings in shares of Edwards Lifesciences by 15.7% during the third quarter. Illinois Municipal Retirement Fund now owns 46,772 shares of the medical research company’s stock worth $4,037,000 after buying an additional 6,359 shares in the last quarter. Bahl & Gaynor LLC boosted its holdings in shares of Edwards Lifesciences by 87.3% in the 3rd quarter. Bahl & Gaynor LLC now owns 9,547 shares of the medical research company’s stock worth $824,000 after acquiring an additional 4,449 shares in the last quarter. AMG National Trust Bank boosted its holdings in shares of Edwards Lifesciences by 6.1% in the 3rd quarter. AMG National Trust Bank now owns 80,054 shares of the medical research company’s stock worth $6,910,000 after acquiring an additional 4,582 shares in the last quarter. Lido Advisors LLC grew its position in Edwards Lifesciences by 5.2% during the 3rd quarter. Lido Advisors LLC now owns 34,192 shares of the medical research company’s stock worth $2,951,000 after acquiring an additional 1,691 shares during the last quarter. Finally, Csenge Advisory Group increased its stake in shares of Edwards Lifesciences by 127.8% in the third quarter. Csenge Advisory Group now owns 14,437 shares of the medical research company’s stock valued at $1,246,000 after buying an additional 8,099 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q3 results and outlook beat expectations. Edwards reported adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion versus $1.68 billion, with sales up 11.2% year over year. Strength in structural heart therapies supported margin growth, and the company raised its full-year adjusted EPS outlook to $2.97–$3.05. Edwards Q3 earnings and revenue
• Positive Sentiment: Growth across key therapies supports the outlook. TMTT sales surged 45.6% and TAVR sales grew 8.8%. The company also expects procedure volumes to benefit from positive study results and expanded Medicare reimbursement. Q3 earnings call highlights
• Positive Sentiment: Clinical findings may broaden the addressable market. PROGRESS Trial data indicated TAVR reduced combined death or heart-failure outcomes versus active surveillance in at-risk patients with moderate aortic stenosis, with fewer heart-failure hospitalizations and better quality-of-life measures. PROGRESS Trial data
• Positive Sentiment: Analysts raised targets and ratings. Several firms lifted price targets, including Barclays to $120, Citigroup to $117 and JPMorgan to $120. Baird and Truist upgraded the stock, while multiple firms reiterated positive ratings, reflecting increased confidence after the quarterly report.
• Negative Sentiment: Competition remains a risk. Edwards’ CEO cautioned that more competition is coming in the TAVR market, which could pressure future growth or market share. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.